We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Transatlantic Partners to Collaborate on Ready-to-Use Products for Microbiological Diagnostics

By LabMedica International staff writers
Posted on 28 Oct 2013
A recently announced transatlantic partnership is dedicated to developing, manufacturing, and marketing ready-to-use media products for microbiological diagnostics and research applications.

The French/German company Sartorius Stedim Biotech (Aubagne, France) - a leading provider of equipment and services for development, quality assurance, and production in the biopharmaceutical industry - and BD Diagnostics (Franklin Lakes, NJ, USA), a leading global medical technology company, recently announced the formation of a collaborative effort to develop, manufacture, and market various ready-to-use, prefilled media products for detection and diagnosis of microorganisms in clinical and research laboratories. More...


Sartorius Stedim Biotech manufactures high quality, single-use filter products for concentration of microbial contaminants, and as part of this partnership agreement, BD Diagnostics will fill special Sartorius single-use products with BD's culture media and supply these back to Sartorius as prepackaged products.

In addition, the companies will be exploring options for extending their existing business relationship by pursuing further innovative solutions in the field of microbiological diagnostics.

“Through our agreement with BD, we have created an excellent collaboration. BD is known worldwide for its expertise in manufacturing and filling of microbial media. BD’s expertise combined with Sartorius Stedim Biotech’s know-how in polymeric technologies and applications will help us further extend our expert capabilities in the field of microbiological monitoring,” said Dominique Baly, member of the Sartorius group executive committee.

“The products we plan to develop under our agreement with Sartorius Stedim Biotech will enhance laboratory efficiencies for our pharmaceutical, biotech, and research customers with these unique product offerings,” said Bob Ferguson, vice president and general manager of BD Diagnostics. “By combining Sartorius Stedim Biotech’s bioprocessing and filtration expertise with BD’s microbiological media capabilities, customers will benefit from improved lab productivity and standardization of sample processing.”

Related Links:
Sartorius Stedim Biotech
BD Diagnostics 



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.